4.6 Article

Absence of P-Selectin in Recipients of Allogeneic Bone Marrow Transplantation Ameliorates Experimental Graft-versus-Host Disease

Journal

JOURNAL OF IMMUNOLOGY
Volume 185, Issue 3, Pages 1912-1919

Publisher

AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.0903148

Keywords

-

Categories

Funding

  1. National Institutes of Health [R01-HL069929, R01-CA107096, R01-AI080455, P01-CA33049, R01-HL095075, P20-CA103694]
  2. U.S. Department of Defense, U.S. Army Medical Research Acquisition Activity Award [W81XWH-09-1-0294]
  3. Ryan Gibson Foundation
  4. William H. Goodwin and Alice Goodwin
  5. Commonwealth Foundation for Cancer Research
  6. Bobby Zucker Memorial Fund
  7. Lymphoma Foundation
  8. National Marrow Donor Program
  9. Marrow Foundation
  10. Lymphoma Research Foundation
  11. Deutsche Krebshilfe
  12. Mildred-Scheel-Stiftung
  13. Deutsche Forschungsgemeinschaft

Ask authors/readers for more resources

Alloreactive T cells are crucial for graft-versus-host disease (GVHD) pathophysiology, and modulating their trafficking patterns has been efficacious in ameliorating experimental disease. We report in this paper that P-selectin, a glycoprotein found on resting and inflamed endothelium, is important for donor alloreactive T cells trafficking into GVHD target organs, such as the intestines and skin. Compared with wild-type (WT) recipients of allogeneic bone marrow transplantation, P-selectin(-/-) recipients exhibit decreased GVHD mortality and decreased GVHD of the skin, liver, and small bowels. This was associated with diminished infiltration of alloactivated T cells into the Peyer's patches and small bowels, coupled with increased numbers of donor T cells in the spleen and secondary lymphoid organs (SLOs). Surprisingly, however, donor T cells deficient for P-selectin glycoprotein ligand 1, the most well described P-selectin ligand, mediated GVHD similar to WT T cells and accumulated in SLO and target organs in similar numbers as WT T cells. This suggests that P-selectin may be required for trafficking into inflamed tissues but not SLO and that donor T cells may use multiple P-selectin ligands apart from P-selectin glycoprotein ligand 1 to interact with P-selectin and traffic into inflamed tissues during GVHD. We conclude that targeting P-selectin may be a viable strategy for GVHD prophylaxis or treatment. The Journal of Immunology, 2010, 185: 1912-1919.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available